Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
ApexOnco Front Page
Recent articles
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Final survival analysis draws a blank, and Lantheus throws in the towel.
Conference activity picks up, with the big one – ASCO – at the end of the month.
Three off-the-shelf mRNA therapies join intismeran autogene.
New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
Antibody-drug conjugates hitting this target abound.
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
